Ellen Sidransky

From WikiMD's Food, Medicine & Wellness Encyclopedia

Ellen Sidransky is a renowned geneticist and physician known for her significant contributions to the field of medical genetics, particularly in the study of Gaucher's disease and Parkinson's disease. She is currently serving as a senior investigator at the National Institutes of Health (NIH).

Early Life and Education[edit | edit source]

Sidransky was born and raised in New York City. She completed her undergraduate studies at Barnard College, where she majored in biology. She then pursued her medical degree from Tulane University School of Medicine.

Career[edit | edit source]

After completing her medical degree, Sidransky joined the National Institutes of Health (NIH) as a clinical associate. She later became a senior investigator at the NIH, where she currently leads a team of researchers studying the genetic components of neurodegenerative diseases.

Sidransky's research primarily focuses on the genetic aspects of Gaucher's disease, a rare genetic disorder, and its connection to Parkinson's disease. Her groundbreaking work has significantly advanced our understanding of these diseases and has paved the way for potential new treatments.

Achievements[edit | edit source]

Sidransky's contributions to the field of medical genetics have been widely recognized. She has received numerous awards and honors, including the Ernest Beutler Prize for Clinical Science and the Lasker Award for Clinical Medical Research.

Publications[edit | edit source]

Sidransky has authored and co-authored numerous scientific articles and papers. Her work has been published in prestigious journals such as The New England Journal of Medicine, Nature Genetics, and The Lancet Neurology.

References[edit | edit source]


External Links[edit | edit source]


Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD